Cheng Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cheng Jiang has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Zhenguo Zhang
School of Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China
8 shared publicationsDailin Liang
Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Tongjiaxiang 24, Nanjing 210009, China; Department of Medicinal Chemistry, China Pharmaceutical University, Tongjiaxiang 24, Nanjing 210009, China
4 shared publications- Li-Li Xu
China Pharmaceutical University
4 shared publications - Qinghua Hu
School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
4 shared publications Chunxiao Liu
School of Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China
3 shared publications- Li Liu
Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing, China
3 shared publications
Latest Publications
- 1 September 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 319
Discovery and characterization of PGC-01: An effective GSDMD-targeting PROTAC
- 1 September 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 319
Discovery and characterization of PGC-01: An effective GSDMD-targeting PROTAC
- 26 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20734-20760
Discovery of a Covalent NLRP3 LRR-Domain Probe: Reversing Renal Fibrosis via Immunometabolic Reprogramming in Organoid and Murine Models
Targeting the NLRP3 inflammasome is critical for treating fibrotic diseases; however, current NACHT domain inhibitors face mutational escape and limited isoform specificity. The autoinhibitory leucine-rich repeat (LRR) domain represents an underexplored pharmacological target. Here, we report QX-31, a novel covalent probe selectively engaging the LRR domain. QX-31 covalently binds to Cysteine 838, stabilizing NLRP3 in an inactive conformation and preventing inflammasome assembly with high selectivity over AIM2 and NLRC4. Furthermore, QX-31 reverses maladaptive immunometabolic reprogramming within the renal microenvironment by blunting the PI3K/AKT/HIF-1α axis, suppressing aberrant glycolysis and glutaminolysis. Evaluated in human kidney organoids and murine models of renal injury (UUO and IRI), QX-31 demonstrated potent antifibrotic efficacy comparable to reference drugs, alongside a favorable safety profile. Collectively, QX-31 serves as a valuable chemical tool, demonstrating that covalent targeting of this conformational regulatory domain is a viable therapeutic strategy for fibrotic diseases.
- 26 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20734-20760
Discovery of a Covalent NLRP3 LRR-Domain Probe: Reversing Renal Fibrosis via Immunometabolic Reprogramming in Organoid and Murine Models
Targeting the NLRP3 inflammasome is critical for treating fibrotic diseases; however, current NACHT domain inhibitors face mutational escape and limited isoform specificity. The autoinhibitory leucine-rich repeat (LRR) domain represents an underexplored pharmacological target. Here, we report QX-31, a novel covalent probe selectively engaging the LRR domain. QX-31 covalently binds to Cysteine 838, stabilizing NLRP3 in an inactive conformation and preventing inflammasome assembly with high selectivity over AIM2 and NLRC4. Furthermore, QX-31 reverses maladaptive immunometabolic reprogramming within the renal microenvironment by blunting the PI3K/AKT/HIF-1α axis, suppressing aberrant glycolysis and glutaminolysis. Evaluated in human kidney organoids and murine models of renal injury (UUO and IRI), QX-31 demonstrated potent antifibrotic efficacy comparable to reference drugs, alongside a favorable safety profile. Collectively, QX-31 serves as a valuable chemical tool, demonstrating that covalent targeting of this conformational regulatory domain is a viable therapeutic strategy for fibrotic diseases.
- 27 September 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 165, 109042
Development of APOBEC3B inhibitors: Recent advances and perspectives
- 27 September 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 165, 109042
Development of APOBEC3B inhibitors: Recent advances and perspectives
- 14 September 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 300, 118171
Progress in small-molecule inhibitors of gasdermin D
- 14 September 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 300, 118171
Progress in small-molecule inhibitors of gasdermin D
- 22 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18272-18288
Design, Synthesis, and Biological Evaluation of Isoform-Selective Akt3 Degraders
Akt3, a serine/threonine kinase within the PI3K-Akt-mTOR signaling pathway, is overactivated in various cancers, making it a promising therapeutic target. The research aimed to create compounds that selectively degrade Akt3, sparing Akt1 and Akt2, to enhance the clinical benefits. A series of compounds with different linkers and E3 ligands were synthesized and evaluated for their degradation potencies and selectivity. The findings showed that the linker length and E3 ligand type significantly influenced Akt3 degradation. Compound 12 was identified as a potent and selective Akt3 degrader in multiple cancer cell lines. Proteomic analysis confirmed the specificity of this degrader for Akt3, with minimal off-target effects. However, compound 12 did not exhibit significant antiproliferative activity in the cancer cell lines.
- 22 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18272-18288
Design, Synthesis, and Biological Evaluation of Isoform-Selective Akt3 Degraders
Akt3, a serine/threonine kinase within the PI3K-Akt-mTOR signaling pathway, is overactivated in various cancers, making it a promising therapeutic target. The research aimed to create compounds that selectively degrade Akt3, sparing Akt1 and Akt2, to enhance the clinical benefits. A series of compounds with different linkers and E3 ligands were synthesized and evaluated for their degradation potencies and selectivity. The findings showed that the linker length and E3 ligand type significantly influenced Akt3 degradation. Compound 12 was identified as a potent and selective Akt3 degrader in multiple cancer cell lines. Proteomic analysis confirmed the specificity of this degrader for Akt3, with minimal off-target effects. However, compound 12 did not exhibit significant antiproliferative activity in the cancer cell lines.
- 31 March 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 123, 130212
Discovery of novel pyridine skeleton derivatives as potent CLK2/3 inhibitors
- 31 March 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 123, 130212
Discovery of novel pyridine skeleton derivatives as potent CLK2/3 inhibitors
- 15 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (17) , 15080-15097
Allosteric Activation of Protein Phosphatase 5 with Small Molecules
The activation of PP5 is essential for a variety of cellular processes, as it participates in a variety of biological pathways by dephosphorylating substrates. However, activation of PP5 by small molecules has been a challenge due to its native "self-inhibition" mechanism, which is controlled by the N-terminal TPR domain and the C-terminal αJ helix. Here, we reported the discovery of DDO-3733, a well-identified TPR-independent PP5 allosteric activator, which facilitates the dephosphorylation process of downstream substrates. Considering the negative regulatory effect of PP5 on heat shock transcription factor HSF1, pharmacologic activation of PP5 by DDO-3733 was found to reduce the HSP90 inhibitor-induced heat shock response. These results provide a chemical tool to advance the exploration of PP5 as a potential therapeutic target and highlight the value of pharmacological activation of PP5 to reduce heat shock toxicity of HSP90 inhibitors.
- 15 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (17) , 15080-15097
Allosteric Activation of Protein Phosphatase 5 with Small Molecules
The activation of PP5 is essential for a variety of cellular processes, as it participates in a variety of biological pathways by dephosphorylating substrates. However, activation of PP5 by small molecules has been a challenge due to its native "self-inhibition" mechanism, which is controlled by the N-terminal TPR domain and the C-terminal αJ helix. Here, we reported the discovery of DDO-3733, a well-identified TPR-independent PP5 allosteric activator, which facilitates the dephosphorylation process of downstream substrates. Considering the negative regulatory effect of PP5 on heat shock transcription factor HSF1, pharmacologic activation of PP5 by DDO-3733 was found to reduce the HSP90 inhibitor-induced heat shock response. These results provide a chemical tool to advance the exploration of PP5 as a potential therapeutic target and highlight the value of pharmacological activation of PP5 to reduce heat shock toxicity of HSP90 inhibitors.
- 3 July 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (14) , 11989-12011
Discovery of a Series of 4-Amide-thiophene-2-carboxyl Derivatives as Highly Potent P2Y14 Receptor Antagonists for Inflammatory Bowel Disease Treatment
The P2Y14 receptor has been proven to be a potential target for IBD. Herein, we designed and synthesized a series of 4-amide-thiophene-2-carboxyl derivatives as novel potent P2Y14 receptor antagonists based on the scaffold hopping strategy. The optimized compound 39 (5-((5-fluoropyridin-2-yl)oxy)-4-(4-methylbenzamido)thiophene-2-carboxylic acid) exhibited subnanomolar antagonistic activity (IC50: 0.40 nM). Moreover, compound 39 demonstrated notably improved solubility, liver microsomal stability, and oral bioavailability. Fluorescent ligand binding assay confirmed that 39 has the binding ability to the P2Y14 receptor, and molecular dynamics (MD) simulations revealed the formation of a unique intramolecular hydrogen bond (IMHB) in the binding conformation. In the experimental colitis mouse model, compound 39 showed a remarkable anti-IBD effect even at low doses. Compound 39, with a potent anti-IBD effect and favorable druggability, can be a promising candidate for further research. In addition, this work lays a strong foundation for the development of P2Y14 receptor antagonists and the therapeutic strategy for IBD.
- 3 July 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (14) , 11989-12011
Discovery of a Series of 4-Amide-thiophene-2-carboxyl Derivatives as Highly Potent P2Y14 Receptor Antagonists for Inflammatory Bowel Disease Treatment
The P2Y14 receptor has been proven to be a potential target for IBD. Herein, we designed and synthesized a series of 4-amide-thiophene-2-carboxyl derivatives as novel potent P2Y14 receptor antagonists based on the scaffold hopping strategy. The optimized compound 39 (5-((5-fluoropyridin-2-yl)oxy)-4-(4-methylbenzamido)thiophene-2-carboxylic acid) exhibited subnanomolar antagonistic activity (IC50: 0.40 nM). Moreover, compound 39 demonstrated notably improved solubility, liver microsomal stability, and oral bioavailability. Fluorescent ligand binding assay confirmed that 39 has the binding ability to the P2Y14 receptor, and molecular dynamics (MD) simulations revealed the formation of a unique intramolecular hydrogen bond (IMHB) in the binding conformation. In the experimental colitis mouse model, compound 39 showed a remarkable anti-IBD effect even at low doses. Compound 39, with a potent anti-IBD effect and favorable druggability, can be a promising candidate for further research. In addition, this work lays a strong foundation for the development of P2Y14 receptor antagonists and the therapeutic strategy for IBD.
- 1 October 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 74, 1-13
Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors
- 1 October 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 74, 1-13
Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors